Find a Clinical Trial

We have included the current major bladder cancer clinical trials that we know about, but you can search for cancer clinical trials on Cancer Research UK's website for more information about individual trials, the time period over which they are running and where the trial is based.

You can also find information on the National Cancer Research Instituteportfolio maps:

You can also ask your clinician or medical team about any clinical trials which may be appropriate for you. 


Current bladder cancer clinical trials



Cancer type: Urinary tract squamous cell carcinoma

This trial is looking at whether immunotherapy with atezolizumab, which is already used in some other types of cancer, could be an effective treatment for patients with this rare form of urinary tract cancer. The aim of the trial is to determine if atezolizumab is effective, tolerable and safe in this patient group.

The trial is currently open at Southampton, UCLH (in London), James Cook (in Middlesborough), Beatson (Glasgow), Edinburgh, Preston, Nottingham, The Christie (Manchester), Royal Marsden (London), Clatterbridge (Liverpool) and Velindre (Cardiff). 

Contact: Chief Investigator, Prof Simon Crabb - 

Video animation about AURORA here:

BRAVO Study 1

Cancer type: High-grade Non-Muscle Invasive Bladder Cancer - diagnosed in previous 24 months but not less than 4 months

A randomised controlled trial of radical cystectomy against intravesical immunotherapy, to understand patients' and health professionals' beliefs about the two interventions and potential barriers to a full clinical trial.

Patients must have received either radical cystectomy or MBCG (or both) and be based in Yorkshire or Humber areas.

Please contact Dr Maureen Twiddy, University of Leeds

Tel: 01134340830


BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways

The aim of the BladderPath study is to improve staging, accelerate treatment and reduce tumour spread in patients with muscle invasive bladder cancer (MIBC) by avoiding TURBT, ultimately improving clinical outcomes. The hypothesis being tested is that substituting TURBT with multiparametric magnetic resonance imaging (mpMRI) (pathway 2) will avoid unnecessary surgery and reduce the time to definitive radical treatment for MIBC.

Centres are opening from September 2018.  Contact Ana Hughes on email for more details.



Cancer type: Muscle-invasive bladder cancer

This trial is looking at the chemotherapy drugs cabazitaxel and cisplatin before surgery to remove bladder cancer.

Cisplatin is a chemotherapy drug often used to treat bladder cancer which is usually given together with another drug such as gemcitabine. In this trial is testing the combination of cisplatin and a drug called cabazitaxel and how well this combination works for treating invasive transitional cell bladder cancer before surgery and more about the side effects.


Cancer type: Transitional cell cancer which has spread

This trial is looking at a chemotherapy drug called cabazitaxel.  It is for people who have transitional cell bladder cancer or cancer of urinary system that has spread into surrounding tissue or another part of the body despite chemotherapy.  The aim of the trial is to see if cabazitaxel helps people with transitional cell cancer that has spread and has got worse despite having platinum chemotherapy.


Cancer type: Low Risk non-invasive bladder cancer

Early stage bladder cancer is usually treated with surgery, which may be followed by intravesical treatment using a chemotherapy drug using mitomycin C.  Sometimes cancer can recur which may mean further surgery.  This trial is comparing mitomycin C with surgery as treatment for bladder cancer that has come back.  The aims of this trial are to find out if mitomycin C alone is an effective treatment to control cancer growth and more about any side effects and how treatment affects quality of life.


Cancer type: Locally advanced and/or metastatic

This is a Phase Ib trial (a very early phase of a clinical trial) of a new drug called AZD4547 in combination with gemcitabine and cisplatin.


This study is using blood and urine samples to develop a test that will show why somebody has blood in their urine - haematuria.   Haematuria can be a symptom of bladder cancer, but there are other possible causes. 

The aim of the trial is to develop a simpler test for the causes of haematuria which may result in more efficient treatment as the cause is determined earlier, and may in the future lead to fewer people needing a cystoscopy.

This trial is recruiting people who have been diagnosed with bladder cancer and also people who have had negative results from tests for bladder cancer.


Cancer type: Muscle-invasive bladder cancer


Invasive bladder cancer is usually treated with surgery or radiotherapy every day for several weeks.  Where surgery is not an option or a patient finds it difficult to cope with daily radiotherapy, people may be offered radiotherapy on a weekly basis for 6 weeks.

This trial is looking at how well this weekly radiotherapy works and at a new way of planning treatment called image guided adaptive planning and whether people who have adaptive radiotherapy have fewer side effects.


Cancer type: non muscle-invasive bladder cancer

This trial is for people with newly diagnosed early bladder cancer or bladder cancer that has come back after initial treatment.

Hyperthermia is a new treatment where the bladder is heated to between 42° and 44° degrees centigrade and mitomycin C is washed through the bladder.

The trial is comparing hyperthermia and mitomycin C with mitomycin C alone. The aim of this trial is to find out which treatment is better at controlling cancer growth, more about the side effect and quality of life.


Cancer Type: Muscle-invasive bladder cancer

This trial is looking at combining 3 different ways to plan radiotherapy treatment for bladder cancer. This is so the doctors can target the cancer more accurately and give a higher dose of radiotherapy than they are normally able to.


This study is looking at some new scans to see if they can show how well treatment has worked in people having chemotherapy before surgery or radiotherapy for bladder cancer.

This trial is looking at new types of scans - a new MRI scan called fMRI (functional MRI scan) which may be better at showing how well treatment is working earlier on; and a new type of PET-CT scan called FLT PET-CT, which may be more effective at showing bladder cancer and giving more information.  You may not get any direct benefit from this trial yourself, but the results will be used to help others with bladder cancer in the future.

The study will recruit people having chemotherapy before radiotherapy or surgery for bladder cancer.


Cancer type: Muscle-invasive bladder cancer

This trial is looking at which combination of drugs works best for treating invasive bladder cancer.  The chemotherapy drugs gemcitabine and cisplatin will be used alongside a new drug called nintedanib for invasive bladder cancer.  Nintedanib (also known as BIBF 1120) is a type of biological therapy.



Cancer Type: Muscle Invasive Bladder Cancer

A trial by AstraZeneca to find out if Durvalumab,combined with the standard of treatment, will work and be safe for the treatment of Muscle Invasive Bladder Cancer. Durvalumab is an antibody (part of the immune system) that is made in the laboratory which may help your immune system to respond to your cancer and prevent or slow its growth. Durvalumab has been approved by the FDA in the USA as therapy for the treatment of urothelial carcinoma that has spread outside the urinary system, for patients whose cancers worsen during or after chemotherapy. Durvalumab is still in the development stage for the treatment of Muscle Invasive Bladder Cancer, and is not approved for treatment of Muscle Invasive Bladder Cancer except for use in research studies like this.

Who can join the trial? Those diagnosed with Muscle Invasive Bladder Cancer that has not spread outside of the bladder or surrounding muscles. Restrictions would include: cancer that has spread to the lymph nodes or elsewhere in the body; if taking immunosuppressive agents; any known autoimmune or inflammatory disorders; a history of another primary malignancy, a history of MI within 6 months prior to randomisation.

Locations: St Bartholomew's Hospital London, Weston Park Hospital Sheffield, Clatterbridge Cancer Centre Wirral, Weston General Hospital Edinburgh, Nottingham University Hospital

Additional Information: Screening period can take up to 28 days prior to randomisation. If randomised enrolled into 1 of 2 treatment groups, therefore there is a 1 in 2 chance of receiving Durvalumab. After 4 cycles of treatment in either group undergo a cystectomy, then depending on what treatment group enrolled into either receive further Durvalumab or monthly monitoring.


Cancer type: Non-invasive bladder cancer, newly diagnosed

This trial is no longer recruiting.

This trial is comparing a white light with a blue light during surgery (transurethral resection of bladder tumour or TURBT) for those recently diagnosed with early bladder cancer.

This trial looks at using a blue light during surgery which shows up a liquid which has been absorbed by the cancer cells and looks red under the blue light.  The aim is to compare this blue light with the standard white light to see which is most effective at showing cancer in the bladder.


This is a phase III multicentre randomised controlled trial to look at the effectiveness, safety and effects on quality of life of adjuvant chemotherapy in patients who have undergone radical nephro-ureterectomy for invasive cancer of the upper urinary tract.


Cancer type: muscle invasive bladder cancer

This trial is for people whose cancer has grown into the muscle wall - muscle invasive bladder cancer.

The standard treatment in the UK for muscle invasive bladder cancer is chemoradiotherapy. This means having chemotherapy and radiotherapy treatment together.

Durvalumab is an immunotherapy. It stimulates the body's immune system to fight cancer cells.

This trial is comparing adding durvalumab to chemoradiotherapy versus chemoradiotherapy alone. The aim of this trial is to find out which treatment is better at controlling cancer growth, to learn more about the side effects and quality of life.

Please contact the Trial team on: 


Cancer type: Advanced bladder cancer which has spread into surrounding tissue or other parts of the body.

This trial is looking at how well a drug called temsirolimus (Torisel) works with cisplatin and gemcitabine chemotherapy in treating advanced transitional cell cancer, how safe this combination is, side effects and the best dose.  Temsirolimus is a type of biological therapy. It is a cancer growth blocker.


Cancer type: Muscle-invasive bladder cancer

This trial is looking at a drug called cetuximab alongside radiotherapy and different types of chemotherapy for muscle-invasive bladder cancer.  Cetuximab is a biological therapy called a monoclonal antibody.  Those taking part may have already had some chemotherapy to shrink their cancer before radiotherapy.

Cancer Research UK Clinical Trials Unit, Institute of Cancer & Genomic Sciences, University of Birmingham.

Are you based in the West Midlands and interested in working with research clinicians and their wider teams to support the development of bladder cancer research? If so, we have a great opportunity for you to use your insight from the patient perspective to shape our future work.


The Institute of Cancer & Genomic Sciences, University of Birmingham. The Institute of Cancer & Genomic Sciences is a research institute with an international reputation and incorporating the Cancer Research UK Clinical Trials Unit (CRCTU), the largest cancer trials units in the UK.


Ben Abbotts
0121 415 8836

Involvement Type:

Developing and reviewing grant proposals, helping to design research, providing a patient's perspective on research


How we help you

Latest News / Events

Understanding Bladder Cancer: Nurses' Education Event: 13 September 2024 11/04/2024

Booking has now opened for the annual major ABC UK Nurses' Education Day. Friday 13 September in Birmingham  Register for your place here: Understanding Bladder Cancer and the Latest Developments Tickets, Fri 13 Sep 2024 at 09:00 | Eventbrite Full programme&nb...

News & Events
Read more

We're on Twitter